To evaluate the feasibility of the JAK2 V617F/Cas12a lateral flow strip assay on the diagnosis of clinical samples, we carried out the analysis of the gDNA extracted from the peripheral blood of 13 healthy donors and one patient with essential thrombocythemia (ET), where the patient was diagnosed with ET according to the 2016 WHO criteria and was demonstrated to have the JAK2 V617F mutation through next-generation sequencing (NGS). The gene discussed is JAK2; the disease is essential thrombocythemia.